Akiram Therapeutics Partners with ITM on Lutetium-177 for Cancer Treatment Advancement

Akiram Therapeutics Expands Cancer Treatment Potential with ITM Partnership

In a significant development within the biotech sector, Akiram Therapeutics has forged a supply agreement with ITM Isotope Technologies Munich SE to acquire Lutetium-177. This partnership is central to the ongoing clinical development of AKIR001, a targeted therapeutic designed for patients affected by solid tumors expressing the CD44v6 marker. Akiram Therapeutics, based in Sweden, is recognized for its innovations in molecular radiotherapy, while ITM is a well-established leader in radiopharmaceutical production.

The agreement, announced on August 20, 2026, confirms ITM's commitment to supply non-carrier-added (n.c.a.) Lutetium-177, ensuring the availability of this critical radioisotope throughout the clinical trial phase of AKIR001. Lutetium-177 is integral to the functioning of this cutting-edge therapy as it acts as the active payload, delivering targeted radiation to tumor cells while minimizing collateral damage to healthy tissues.

A Step Forward in Targeted Cancer Therapy

Marika Nestor, CEO of Akiram Therapeutics, expressed her enthusiasm regarding the partnership with ITM, stating, “We are pleased to partner with ITM, a leading global producer and supplier of n.c.a. Lu-177, as we continue advancing AKIR001 through clinical development.” This relationship not only secures a vital component for their investigational therapy but also marks a pivotal milestone in tackling the complexities associated with aggressive cancers.

AKIR001 is envisioned as a promising entry in the realm of targeted radiopharmaceuticals. It combines Lutetium-177 with a proprietary antibody engineered to target CD44v6, a protein associated with various aggressive tumors. By honing in on this specific cancer marker, AKIR001 aims to provide a mechanism that intensifies the therapeutic impact on tumor cells while sparing healthy cells from harmful radiation exposure. This strategic approach to cancer treatment represents a paradigm shift in how oncological therapies can be administered.

Currently, AKIR001 is undergoing clinical evaluation in a Phase I trial at the prestigious Karolinska University Hospital in Stockholm. Recruitment focuses on patients suffering from irresectable or metastatic tumors that express the CD44v6 target, covering a spectrum of malignancies, including lung, head and neck, thyroid, and gynecological cancers.

ITM’s Role and Commitment

ITM's CEO, Dr. Andrew Cavey, highlighted the importance of their collaboration for advancing innovative therapeutic options for challenging cancers. He stated, “This agreement allows us to provide a dependable, high-quality source of n.c.a. Lu-177 for their clinical trials and research that may, in time, prove genuinely transformative.” ITM's expertise in consistent and high-quality radiopharmaceuticals ensures that Akiram can effectively progress through the various stages of clinical testing necessary for FDA approval and market introduction.

In summary, the partnership between Akiram Therapeutics and ITM marks an exciting advancement in the fight against cancer. AKIR001 holds promise not only as a treatment option for patients with treatment-resistant cancer types but also exemplifies the innovative methodologies being explored in the biotechnology industry.

For further inquiries regarding the study or the companies involved, interested parties are encouraged to contact Akiram Therapeutics and ITM directly. This partnership reinforces the commitment of both organizations to push the boundaries of what is possible in cancer treatment, potentially changing the lives of patients around the world.